Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])

被引：0
|
作者：
Tabernero, J.
Aranda, E.
Gomez, A.
Massuti, B.
Sastre, J.
Abad, A.
Valladares, M.
Rivera, F.
Safont, M.
Diaz-Rubio, E.
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Gen Alicante, Alicante, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Univ Hosp Germans Trias & Pujol ICO, Barcelona, Spain
[6] Complejo Hosp Univ La Coruna, La Coruna, Spain
[7] Hosp Marques de Valdecilla, Cantabria, Spain
[8] Hosp Gen Valencia, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3501
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer
    Saltz, L.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, T.
    Cassidy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] SIRFLOX: RANDOMISED PHASE III TRIAL COMPARING FIRST-LINE MFOLFOX6 ± BEVACIZUMAB (BEV) VERSUS MFOLFOX6 ± BEV plus SELECTIVE INTERNAL RADIATION THERAPY (SIRT) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) - ANALYSIS BY PRESENCE OR ABSENCE OF EXTRA-HEPATIC METASTASES, BEV TREATMENT AND SITE OF FIRST PROGRESSION
    Gibbs, Peter
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget
    Strickland, Andrew
    Ferguson, Tom
    Rodrigez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Gebski, Val
    Van Buskirk, Mark
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 68 - 69
  • [33] Induction treatment in first-line with chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study
    Tournigand, Christophe
    Scheithauer, Werner
    Samson, Benoit
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    Chibaudel, Benoist
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
    Aranda, E.
    Garcia-Alfonso, P.
    Benavides, M.
    Sanchez Ruiz, A.
    Guillen-Ponce, C.
    Safont, M. J.
    Alcaide, J.
    Gomez, A.
    Lopez, R.
    Manzano, J. L.
    Mendez Urena, M.
    Sastre, J.
    Rivera, F.
    Gravalos, C.
    Garcia, T.
    Martin-Valades, J. I.
    Falco, E.
    Navalon, M.
    Gonzalez Flores, E.
    Garcia Tapiador, A. Ma
    Lopez Munoz, A. Ma
    Barrajon, E.
    Reboredo, M.
    Garcia Teijido, P.
    Viudez, A.
    Cardenas, N.
    Diaz-Rubio, E.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 263 - 272
  • [35] Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.
    Dominik, Modest
    Ludwig, Fischer von Weikersthal
    Thomas, Decker
    Ursula, Vehling-Kaiser
    Jens, Uhlig
    Michael, Schenk
    Jens, Freiberg-Richter
    Bettina, Peuser
    Claudio, Denzlinger
    Christina, Peveling Genannt Reddemann
    Ullrich, Graeven
    Gunter, Schuch
    Ingo, Schwaner
    Arndt, Stahler
    Andreas, Jung
    Swantje, Held
    Sebastian, Stintzing
    Clemens, Giessen-Jung
    Volker, Heinemann
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Fluoropyrimidine (FP) plus bevacizumab (BEV) plus atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
    Grothey, A.
    Tabernero, J.
    Arnold, D.
    De Gramont, A.
    Ducreux, M. P.
    O'Dwyer, P. J.
    Van Cutsem, E.
    Bosanac, I.
    Srock, S.
    Mancao, C.
    Gilberg, F.
    Winter, J.
    Schmoll, H-J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
    A. Carrato
    M. Benavides
    B. Massutí
    R. Ferreiro-Monteagudo
    P. García Alfonso
    E. Falcó
    M. Reboredo
    T. Cano
    J. Gallego
    J. M. Viéitez
    L. Layos
    A. Salud
    E. Polo
    E. Dotor
    G. Durán-Ogalla
    M. Rodriguez-Garrote
    A. Calvo
    E. Grande
    E. Aranda
    BMC Cancer, 19
  • [38] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [39] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [40] First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
    Carrato, A.
    Benavides, M.
    Massuti, B.
    Ferreiro-Monteagudo, R.
    Garcia Alfonso, P.
    Falco, E.
    Reboredo, M.
    Cano, T.
    Gallego, J.
    Vieitez, J. M.
    Layos, L.
    Salud, A.
    Polo, E.
    Dotor, E.
    Duran-Ogalla, G.
    Rodriguez-Garrote, M.
    Calvo, A.
    Grande, E.
    Aranda, E.
    BMC CANCER, 2019, 19 (1)
12345